Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Oct;39(10):2248–2252. doi: 10.1128/aac.39.10.2248

Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.

E Cambau 1, E Perani 1, C Dib 1, C Petinon 1, J Trias 1, V Jarlier 1
PMCID: PMC162924  PMID: 8619577

Abstract

In Pseudomonas aeruginosa, resistance to imipenem is mainly related to a lack of protein OprD and resistance to fluoroquinolones is mainly related to alterations in DNA gyrase. However, strains cross resistant to fluoroquinolones and imipenem have been selected in vitro and in vivo with fluoroquinolones. We investigated the mechanisms of resistance to fluoroquinolones in 30 clinical strains of P. aeruginosa resistant to ciprofloxacin (mean MIC, >8 micrograms/ml), 20 of which were also resistant to imipenem (mean MIC, >16 micrograms/ml). By immunoblotting, OprD levels were markedly decreased in all of the imipenem-resistant strains. Plasmids carrying the wild-type gyrA gene (pPAW207) or gyrB gene (pPBW801) of Escherichia coli were introduced into each strain by transformation. MICs of imipenem did not change after transformation, whereas those of ciprofloxacin and sparfloxacin dramatically decreased (25- to 70-fold) for all of the strains. For 28 of them (8 susceptible and 20 resistant to imipenem), complementation was obtained with pPAW207 but not with pPBW801. After complementation, the geometric mean MICs of ciprofloxacin and sparfloxacin (MICs of 0.3 microgram/ml and 0.5 microgram/ml, respectively) were as low as those for wild-type strains. Complementation was obtained only with pPBW801 for one strain and with pPAW207 and pPBW801 for one strain highly resistant to fluoroquinolones. These results demonstrate that in clinical practice, gyrA mutations are the major mechanism of resistance to fluoroquinolones even in the strains of P. aeruginosa resistant to imipenem and lacking OprD, concomitant resistance to these drugs being the result of the addition of at least two independent mechanisms.

Full Text

The Full Text of this article is available as a PDF (191.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aubert G., Pozzetto B., Dorche G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother. 1992 Mar;29(3):307–312. doi: 10.1093/jac/29.3.307. [DOI] [PubMed] [Google Scholar]
  2. Büscher K. H., Cullmann W., Dick W., Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother. 1987 May;31(5):703–708. doi: 10.1128/aac.31.5.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cambau E., Gutmann L. Mechanisms of resistance to quinolones. Drugs. 1993;45 (Suppl 3):15–23. doi: 10.2165/00003495-199300453-00005. [DOI] [PubMed] [Google Scholar]
  4. Celesk R. A., Robillard N. J. Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1989 Nov;33(11):1921–1926. doi: 10.1128/aac.33.11.1921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chamberland S., Bayer A. S., Schollaardt T., Wong S. A., Bryan L. E. Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob Agents Chemother. 1989 May;33(5):624–634. doi: 10.1128/aac.33.5.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Daikos G. L., Lolans V. T., Jackson G. G. Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones. Antimicrob Agents Chemother. 1988 May;32(5):785–787. doi: 10.1128/aac.32.5.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fasching C. E., Tenover F. C., Slama T. G., Fisher L. M., Sreedharan S., Oram M., Willard K., Sinn L. M., Gerding D. N., Peterson L. R. gyrA mutations in ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus from Indiana, Minnesota, and Tennessee. J Infect Dis. 1991 Nov;164(5):976–979. doi: 10.1093/infdis/164.5.976. [DOI] [PubMed] [Google Scholar]
  8. Fukuda H., Hosaka M., Hirai K., Iyobe S. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother. 1990 Sep;34(9):1757–1761. doi: 10.1128/aac.34.9.1757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fukuda H., Hosaka M., Iyobe S., Gotoh N., Nishino T., Hirai K. nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995 Mar;39(3):790–792. doi: 10.1128/AAC.39.3.790. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol. 1983 Jun 5;166(4):557–580. doi: 10.1016/s0022-2836(83)80284-8. [DOI] [PubMed] [Google Scholar]
  11. Hane M. W., Wood T. H. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol. 1969 Jul;99(1):238–241. doi: 10.1128/jb.99.1.238-241.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heisig P., Wiedemann B. Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria. Antimicrob Agents Chemother. 1991 Oct;35(10):2031–2036. doi: 10.1128/aac.35.10.2031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hirai K., Suzue S., Irikura T., Iyobe S., Mitsuhashi S. Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1987 Apr;31(4):582–586. doi: 10.1128/aac.31.4.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Huang H., Hancock R. E. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa. J Bacteriol. 1993 Dec;175(24):7793–7800. doi: 10.1128/jb.175.24.7793-7800.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Sep;38(9):2014–2023. doi: 10.1128/aac.38.9.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jakics E. B., Iyobe S., Hirai K., Fukuda H., Hashimoto H. Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1992 Nov;36(11):2562–2565. doi: 10.1128/aac.36.11.2562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kaatz G. W., Seo S. M. Mechanism of ciprofloxacin resistance in Pseudomonas aeruginosa. J Infect Dis. 1988 Sep;158(3):537–541. doi: 10.1093/infdis/158.3.537. [DOI] [PubMed] [Google Scholar]
  18. Kureishi A., Diver J. M., Beckthold B., Schollaardt T., Bryan L. E. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob Agents Chemother. 1994 Sep;38(9):1944–1952. doi: 10.1128/aac.38.9.1944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Li X. Z., Livermore D. M., Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother. 1994 Aug;38(8):1732–1741. doi: 10.1128/aac.38.8.1732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lynch M. J., Drusano G. L., Mobley H. L. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1987 Dec;31(12):1892–1896. doi: 10.1128/aac.31.12.1892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Masecar B. L., Celesk R. A., Robillard N. J. Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Feb;34(2):281–286. doi: 10.1128/aac.34.2.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Masuda N., Ohya S. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1992 Sep;36(9):1847–1851. doi: 10.1128/aac.36.9.1847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Masuda N., Sakagawa E., Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995 Mar;39(3):645–649. doi: 10.1128/AAC.39.3.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Michea-Hamzehpour M., Lucain C., Pechere J. C. Resistance to pefloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991 Mar;35(3):512–518. doi: 10.1128/aac.35.3.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Michéa-Hamzehpour M., Furet Y. X., Pechère J. C. Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1991 Oct;35(10):2091–2097. doi: 10.1128/aac.35.10.2091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Nakamura S., Nakamura M., Kojima T., Yoshida H. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother. 1989 Feb;33(2):254–255. doi: 10.1128/aac.33.2.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ogle J. W., Reller L. B., Vasil M. L. Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe. J Infect Dis. 1988 Apr;157(4):743–748. doi: 10.1093/infdis/157.4.743. [DOI] [PubMed] [Google Scholar]
  28. Piddock L. J., Hall M. C., Bellido F., Bains M., Hancock R. E. A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1992 May;36(5):1057–1061. doi: 10.1128/aac.36.5.1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Quinn J. P., Dudek E. J., DiVincenzo C. A., Lucks D. A., Lerner S. A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986 Aug;154(2):289–294. doi: 10.1093/infdis/154.2.289. [DOI] [PubMed] [Google Scholar]
  30. Robillard N. J. Broad-host-range gyrase A gene probe. Antimicrob Agents Chemother. 1990 Oct;34(10):1889–1894. doi: 10.1128/aac.34.10.1889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Robillard N. J., Scarpa A. L. Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother. 1988 Apr;32(4):535–539. doi: 10.1128/aac.32.4.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rådberg G., Nilsson L. E., Svensson S. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin. Antimicrob Agents Chemother. 1990 Nov;34(11):2142–2147. doi: 10.1128/aac.34.11.2142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Soussy C. J., Wolfson J. S., Ng E. Y., Hooper D. C. Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob Agents Chemother. 1993 Dec;37(12):2588–2592. doi: 10.1128/aac.37.12.2588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Takiff H. E., Salazar L., Guerrero C., Philipp W., Huang W. M., Kreiswirth B., Cole S. T., Jacobs W. R., Jr, Telenti A. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother. 1994 Apr;38(4):773–780. doi: 10.1128/aac.38.4.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Trias J., Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Jan;34(1):52–57. doi: 10.1128/aac.34.1.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yoshida H., Nakamura M., Bogaki M., Nakamura S. Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990 Jun;34(6):1273–1275. doi: 10.1128/aac.34.6.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Yoshida T., Muratani T., Iyobe S., Mitsuhashi S. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1994 Jul;38(7):1466–1469. doi: 10.1128/aac.38.7.1466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Zhanel G. G., Karlowsky J. A., Saunders M. H., Davidson R. J., Hoban D. J., Hancock R. E., McLean I., Nicolle L. E. Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. Antimicrob Agents Chemother. 1995 Feb;39(2):489–495. doi: 10.1128/aac.39.2.489. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES